跳至主要内容
临床试验/NCT03608761
NCT03608761已完成4 期

Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study

Hospital Nacional Profesor Alejandro Posadas1 个研究点 分布在 1 个国家目标入组 21 人开始时间: 2017年2月6日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
21
试验地点
1
主要终点
OSDI

研究概览

简要总结

Two-period, controlled, randomized and open clinical trial. The sample was composed of adult women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who attended the ocular surface office, derived from the general ophthalmology clinic, from the Rheumatology or Immunology department. The three interventions were randomized: autologous serum (GSA), Rebamipida 2% (GR) and a combined treatment (GSAR). The following were used as outcome measures: OSDI self-administered questionnaire (Ocular Surface Disease Index), tear-rupture time (BUT), fluorescein staining, Bengal Rose staining and Schirmer's test without anesthesia to assess the answer to each treatment

详细描述

After having borrowed to participate in the study, we proceeded to the random assignment of each intervention as follow: the last 2 numbers of the clinical history, typical of the ocular surface office, were taken and they were placed in a list in order of lower to higher. Then, each of them was assigned to a number from a table of random numbers. The list was rearranged from lowest to highest using the assigned random number. Finally, the treatment was assigned by simple randomization without replacement. In this way, the subject with the lowest random number, the correspondence in the first treatment drawn. It was continued in the same way, respecting the order assigned by random numbers until completing the 21 subjects.

Three groups of 7 subjects each were formed in this way: treatment group or group Rebamipida (GR); standard treatment group or autologous serum group (GSA) and mixed group or serum and Rebamipide group (GSAR).

Before beginning with the assigned treatment, all the participants was started a period of wash-out of any medicine they were ussing, that least for two weeks. The participants were asked to suspend all the drops that they been used until then (antibiotics, corticosteroids, cyclosporine, artificial tears, autologous serum, etc.), and to place them using only artificial tears (sodium carboxymethyl cellulose). 1%, AUCIC 1%) four times a day in all cases. The purpose was to minimize the effect of the medication that could interfere with the results obtained from the treatments tested. The two week period also allowed the hemotherapy service to prepare the autologous serum for the subjects assigned to this group and initiate the treatment without delays.

Immediately after the washout period, the subjects began to receive the last treatments for 90 days.

After the first intervention cycle and with the objective of influencing the treatment cycle of the first treatment cycle, a second washing period of two weeks duration was carried out.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Treatment
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • diagnosis of Sjögren's syndrome
  • dry eye symtoms

排除标准

  • history of ocular surface surgery less than one year or intraocular surgery less than three months in one or both eyes
  • chronic use of drops in one of both eyes (e.g. : treatment for glaucoma)
  • anterior segment disease (ocular scar pemphigoid, Stenvens Jhonson syndrome)
  • presence of punctung plug (lacrimal plug) inserted in one or both lower lacrimal points
  • systemic viral infections (Hepatitis B, Hepatitis C, HIV)

研究组 & 干预措施

Rebamipide 2%

Experimental
    • wash-out: 2 weeks
    • rebamipide 2% four times a day for 3 months
    • controls will be taken at day zero, 30 and 90.
    • wash-out: 2 weeks
    • autologous serum for 3 months

干预措施: Rebamipide (Drug)

autologous serum and rebamipide 2%

Experimental

rebamipide 2% and autologous serum four times a day for 3 months separately by 1 minute between each other controls will be taken at day zero, 30 and 90. this group will not be crossed

干预措施: autologous serum and rebamipide 2% (Other)

Autologous serum

Experimental
    • wash-out: 2 weeks
    • autologous serum four times a day for 3 months
    • controls will be taken at day zero, 30 and 90.
    • wash-out: 2 weeks
    • rebamipe 2% for 3 months

干预措施: autologous serum (Biological)

结局指标

主要结局

OSDI

时间窗: through study completion, an average of 7 months

ocular surface disease index

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验